How tumours escape mass destruction
- PMID: 18836470
- DOI: 10.1038/onc.2008.268
How tumours escape mass destruction
Abstract
It is now well established that the immune system can control neoplastic development and growth in a process termed immunosurveillance. A link between host immunosurveillance and neoplastic progression is revealed in cases where the immune response becomes compromised due to genetic or other pathological conditions, resulting in a substantially increased incidence and rate of spontaneous tumour formation in both preclinical animal models and patients. It has also been demonstrated in tumour-bearing hosts that the tumorigenic process itself can promote a state of immunosuppression that, in turn, facilitates neoplastic progression. The ability of neoplastic populations to induce a hostile microenvironment through both cell contact-dependent and -independent immunosuppressive networks is a significant barrier to effective cell-mediated immunity and immunotherapy. Thus, a competent immune system is integral for the control of neoplastic disease, and dissecting the plethora of tumour escape mechanisms that disrupt this essential host defense capability is integral for the development of effective immunotherapeutic paradigms.
Similar articles
-
Tumor-host immune interactions and dendritic cell dysfunction.Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7. Adv Cancer Res. 2004. PMID: 15530555 Review.
-
Immunosuppressive networks in the tumour environment and their effect in dendritic cells.Biochim Biophys Acta. 2009 Jan;1795(1):16-24. doi: 10.1016/j.bbcan.2008.07.001. Epub 2008 Jul 15. Biochim Biophys Acta. 2009. Retraction in: Biochim Biophys Acta. 2013 Apr;1835(2):259. PMID: 18675885 Retracted. Review.
-
The tumor microenvironment and its role in promoting tumor growth.Oncogene. 2008 Oct 6;27(45):5904-12. doi: 10.1038/onc.2008.271. Oncogene. 2008. PMID: 18836471 Free PMC article. Review.
-
Immunological responses can have both pro- and antitumour effects: implications for immunotherapy.Expert Rev Mol Med. 2007 Feb 7;9(4):1-20. doi: 10.1017/S1462399407000233. Expert Rev Mol Med. 2007. PMID: 17284328 Review.
-
Improving cancer immunotherapy by targeting tumor-induced immune suppression.Cancer Metastasis Rev. 2011 Mar;30(1):125-40. doi: 10.1007/s10555-011-9280-5. Cancer Metastasis Rev. 2011. PMID: 21249424 Review.
Cited by
-
Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence.Acta Pharm Sin B. 2024 Jan;14(1):335-349. doi: 10.1016/j.apsb.2023.08.034. Epub 2023 Sep 9. Acta Pharm Sin B. 2024. PMID: 38261838 Free PMC article.
-
T cell density and location can influence the prognosis of ovarian cancer.Pathol Oncol Res. 2010 Sep;16(3):361-70. doi: 10.1007/s12253-009-9230-5. Epub 2009 Dec 19. Pathol Oncol Res. 2010. PMID: 20024633
-
Stem cell replication, somatic mutations and role of randomness in the development of cancer.Eur J Epidemiol. 2019 May;34(5):439-445. doi: 10.1007/s10654-018-0477-6. Epub 2019 Jan 8. Eur J Epidemiol. 2019. PMID: 30623292 Free PMC article. Review.
-
Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation.Sci Rep. 2021 Oct 26;11(1):21072. doi: 10.1038/s41598-021-00626-7. Sci Rep. 2021. PMID: 34702927 Free PMC article.
-
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives.Front Med. 2019 Aug;13(4):438-450. doi: 10.1007/s11684-018-0674-4. Epub 2019 Mar 2. Front Med. 2019. PMID: 30826965 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
